139377-33-6

Basic information

• Product Name: Benzeneacetic acid, 3-(phenylmethoxy)-, phenylmethyl ester
• CAS NO: 139377-33-6
• Molecular Formula: C22H20O3
• Molecular Weight: 332.399
• Mol File: 139377-33-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, 3-(phenylmethoxy)-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, 3-(phenylmethoxy)-, phenylmethyl ester(139377-33-6)
• EPA Substance Registry System: Benzeneacetic acid, 3-(phenylmethoxy)-, phenylmethyl ester(139377-33-6)

Safety Data

• Hazardous Substances Data: 139377-33-6(Hazardous Substances Data)

Upstream product

• 621-37-4 m-hydroxyphenylacetic acid 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 

Downstream Products

• 79755-51-4 1-(3-benzyloxyphenyl)-2-chloropropan 
• 79755-50-3 1-(3-benzyloxyphenyl)propan-2-ol 
• 62932-75-6 <3-(benzyloxy)phenyl>acetone 
• 79755-52-5 2-chloro-1-(3-hydroxyphenyl)propane 
• 64479-84-1 1-(3-hydroxyphenyl)propan-2-one 
• 79755-53-6 1-(3-hydroxyphenyl)prop-1-ene 
• 1860-58-8 3-benzyloxyphenylacetic acid 
• 160721-29-9 methyl 2-<3-(benzyloxy)phenyl>-N-methyl acetohydroxamate 

Relevant articles and documents

Efficient synthesis of 1-Benzyloxyphenyl-3-phenylacetones

1-[(Benzyloxy)phenyl]-3-phenylacetones 1a-c have been conveniently synthesized by acylation of the PhCH2Li-DABCO complex with their respective N-methyl O-methyl hydroxamates 5a-c. In four steps, ketones 1a-c having ortho-, meta- and para-benzyloxy substituents were obtained in 42-51% overall yields from commercially available 2-(hydroxyphenyl)acetic acids.

BETA-LACTAMASE INHIBITORS

Disclosed herein are alpha-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising alpha-aminoboronic acids and methods of use thereof.

Compounds and methods for modulation of estrogen receptors

Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and/o